vs
GENMAB A/S（GMAB）与Loews Corporation（L）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是Loews Corporation的1.1倍（$925.0M vs $827.0M），Loews Corporation净利率更高（48.6% vs 36.3%，领先12.3%），GENMAB A/S同比增速更快（18.7% vs 4.8%），Loews Corporation自由现金流更多（$426.0M vs $327.0M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
Loews Corporation是一家总部位于美国的多元化综合企业集团，旗下子公司业务覆盖财产保险、天然气管道运输、酒店运营、油气勘探生产等核心领域，主要服务北美市场的商业、消费者及工业客户。
GMAB vs L — 直观对比
营收规模更大
GMAB
是对方的1.1倍
$827.0M
营收增速更快
GMAB
高出13.9%
4.8%
净利率更高
L
高出12.3%
36.3%
自由现金流更多
L
多$99.0M
$327.0M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $827.0M |
| 净利润 | $336.0M | $402.0M |
| 毛利率 | 93.8% | — |
| 营业利润率 | 38.9% | 65.4% |
| 净利率 | 36.3% | 48.6% |
| 营收同比 | 18.7% | 4.8% |
| 净利润同比 | 65.5% | 115.0% |
| 每股收益（稀释后） | $5.42 | $1.93 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABL
| Q4 25 | — | $827.0M | ||
| Q3 25 | — | $732.0M | ||
| Q2 25 | $925.0M | $769.0M | ||
| Q1 25 | — | $846.0M | ||
| Q4 24 | — | $789.0M | ||
| Q3 24 | — | $683.0M | ||
| Q2 24 | $779.0M | $711.0M | ||
| Q1 24 | — | $710.0M |
净利润GMABL
| Q4 25 | — | $402.0M | ||
| Q3 25 | — | $504.0M | ||
| Q2 25 | $336.0M | $391.0M | ||
| Q1 25 | — | $370.0M | ||
| Q4 24 | — | $187.0M | ||
| Q3 24 | — | $401.0M | ||
| Q2 24 | $203.0M | $369.0M | ||
| Q1 24 | — | $457.0M |
毛利率GMABL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 93.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 96.4% | — | ||
| Q1 24 | — | — |
营业利润率GMABL
| Q4 25 | — | 65.4% | ||
| Q3 25 | — | 94.1% | ||
| Q2 25 | 38.9% | 70.1% | ||
| Q1 25 | — | 60.8% | ||
| Q4 24 | — | 23.8% | ||
| Q3 24 | — | 80.5% | ||
| Q2 24 | 30.3% | 71.3% | ||
| Q1 24 | — | 88.6% |
净利率GMABL
| Q4 25 | — | 48.6% | ||
| Q3 25 | — | 68.9% | ||
| Q2 25 | 36.3% | 50.8% | ||
| Q1 25 | — | 43.7% | ||
| Q4 24 | — | 23.7% | ||
| Q3 24 | — | 58.7% | ||
| Q2 24 | 26.1% | 51.9% | ||
| Q1 24 | — | 64.4% |
每股收益（稀释后）GMABL
| Q4 25 | — | $1.93 | ||
| Q3 25 | — | $2.43 | ||
| Q2 25 | $5.42 | $1.87 | ||
| Q1 25 | — | $1.74 | ||
| Q4 24 | — | $0.87 | ||
| Q3 24 | — | $1.82 | ||
| Q2 24 | $3.13 | $1.67 | ||
| Q1 24 | — | $2.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $6.0B |
| 总债务越低越好 | — | $8.4B |
| 股东权益账面价值 | $5.3B | $18.7B |
| 总资产 | $6.5B | $86.3B |
| 负债/权益比越低杠杆越低 | — | 0.45× |
8季度趋势，按日历期对齐
现金及短期投资GMABL
| Q4 25 | — | $6.0B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | $1.3B | $4.5B | ||
| Q1 25 | — | $4.4B | ||
| Q4 24 | — | $4.6B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | $622.0M | $4.9B | ||
| Q1 24 | — | $5.4B |
总债务GMABL
| Q4 25 | — | $8.4B | ||
| Q3 25 | — | $8.4B | ||
| Q2 25 | — | $7.9B | ||
| Q1 25 | — | $8.4B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.8B | ||
| Q2 24 | — | $8.6B | ||
| Q1 24 | — | $8.4B |
股东权益GMABL
| Q4 25 | — | $18.7B | ||
| Q3 25 | — | $18.3B | ||
| Q2 25 | $5.3B | $17.5B | ||
| Q1 25 | — | $17.2B | ||
| Q4 24 | — | $17.1B | ||
| Q3 24 | — | $17.4B | ||
| Q2 24 | $4.4B | $16.4B | ||
| Q1 24 | — | $16.2B |
总资产GMABL
| Q4 25 | — | $86.3B | ||
| Q3 25 | — | $85.9B | ||
| Q2 25 | $6.5B | $84.7B | ||
| Q1 25 | — | $83.1B | ||
| Q4 24 | — | $81.9B | ||
| Q3 24 | — | $83.6B | ||
| Q2 24 | $5.6B | $81.1B | ||
| Q1 24 | — | $80.9B |
负债/权益比GMABL
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.45× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.51× | ||
| Q2 24 | — | 0.52× | ||
| Q1 24 | — | 0.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $617.0M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $426.0M |
| 自由现金流率自由现金流/营收 | 35.4% | 51.5% |
| 资本支出强度资本支出/营收 | 2.4% | 23.1% |
| 现金转化率经营现金流/净利润 | 1.04× | 1.53× |
| 过去12个月自由现金流最近4个季度 | — | $2.7B |
8季度趋势，按日历期对齐
经营现金流GMABL
| Q4 25 | — | $617.0M | ||
| Q3 25 | — | $920.0M | ||
| Q2 25 | $349.0M | $1.0B | ||
| Q1 25 | — | $736.0M | ||
| Q4 24 | — | $941.0M | ||
| Q3 24 | — | $934.0M | ||
| Q2 24 | $438.0M | $952.0M | ||
| Q1 24 | — | $198.0M |
自由现金流GMABL
| Q4 25 | — | $426.0M | ||
| Q3 25 | — | $764.0M | ||
| Q2 25 | $327.0M | $872.0M | ||
| Q1 25 | — | $638.0M | ||
| Q4 24 | — | $767.0M | ||
| Q3 24 | — | $794.0M | ||
| Q2 24 | $430.0M | $793.0M | ||
| Q1 24 | — | $39.0M |
自由现金流率GMABL
| Q4 25 | — | 51.5% | ||
| Q3 25 | — | 104.4% | ||
| Q2 25 | 35.4% | 113.4% | ||
| Q1 25 | — | 75.4% | ||
| Q4 24 | — | 97.2% | ||
| Q3 24 | — | 116.3% | ||
| Q2 24 | 55.2% | 111.5% | ||
| Q1 24 | — | 5.5% |
资本支出强度GMABL
| Q4 25 | — | 23.1% | ||
| Q3 25 | — | 21.3% | ||
| Q2 25 | 2.4% | 17.4% | ||
| Q1 25 | — | 11.6% | ||
| Q4 24 | — | 22.1% | ||
| Q3 24 | — | 20.5% | ||
| Q2 24 | 1.0% | 22.4% | ||
| Q1 24 | — | 22.4% |
现金转化率GMABL
| Q4 25 | — | 1.53× | ||
| Q3 25 | — | 1.83× | ||
| Q2 25 | 1.04× | 2.57× | ||
| Q1 25 | — | 1.99× | ||
| Q4 24 | — | 5.03× | ||
| Q3 24 | — | 2.33× | ||
| Q2 24 | 2.16× | 2.58× | ||
| Q1 24 | — | 0.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
L
| Transportation And Storage Of Natural Gas And NG Ls And Ethane Supply And Transportation Services | $601.0M | 73% |
| Lodging And Related Services | $226.0M | 27% |
